Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetically-defined AML subgroups represent diverse epigenetic heterogeneity landscape
    Meeting Abstract

    Li, S.; Chen, X.; Wang, J.; Meydan, C.; Glass, J. L.; Shih, A. H.; Valk, P. J. M.; Delwel, R.; Levine, R. L.; Mason, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations
    Meeting Abstract

    Larson, R. A.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S. M.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Dohner, K.; Marcucci, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Biomarkers for predicting toxicity and response in adult acute lymphoblastic leukemia (ALL) patients treated with blinatumomab
    Meeting Abstract

    King, A. C.; Daley, R. J.; Horvat, T. Z.; Hsu, M.; Park, J. H.
    Blood (2017)

    Fulltext@MSK | Save
  • Results of a phase 3 study of elderly patients with newly diagnosed AML treated with sapacitabine and decitabine administered in alternating cycles
    Meeting Abstract

    Kantarjian, H. M.; Begna, K. H.; Altman, J. K.; Goldberg, S. L.; Sekeres, M. A.; Strickland, S. A.; Rubenstein, S. E.; Arellano, M. L.; Claxton, D. F.; Baer, M. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Characteristics and outcome of patients with acute myeloid leukemia and t(6;9)(p22;q34)
    Meeting Abstract

    Kayser, S.; Hills, R. K.; Luskin, M. R.; Brunner, A. M.; Shaw, C.; Westermann, J.; Menghrajani, K.; Baer, M. R.; Elliott, M. A.; Perl, A. E.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment
    Meeting Abstract

    Jurcic, J. G.; Raza, A.; Vlad, G.; Stein, E. M.; Roshal, M.; Bixby, D. L.; Boyer, D. F.; Vigil, C. E.; Syrbu, S.; Sekeres, M. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: Results by 3-month BCR-ABL1 transcript level
    Meeting Abstract

    Hochhaus, A.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Development of JCARH125: Optimization of a fully human anti-BCMA CAR for use in the treatment of multiple myeloma
    Meeting Abstract

    Harrington, K.; Wu, R.; Hauskins, C.; Amin, R.; Long, T.; Chen, A.; Rahardjo, A.; Thayer, C.; Navvaro, G.; Myers, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: 18 month follow-up
    Meeting Abstract

    Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutierrez, V. G.; more...
    Blood (2017)

    Fulltext@MSK | Save